Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2005;331 (1 October), doi:10.1136/bmj.331.7519.0
Routine use of misoprostol as a sublingual tablet may reduce postpartum morbidity and mortality in developing countries, where many pregnant women are anaemic. In a randomised double blind placebo controlled trial of 661 women in Guinea-Bissau, Høj and colleagues (p 723) found that 600 µg misoprostol significantly reduced the incidence of severe postpartum haemorrhage. Compared with women randomised to placebo, women who received the drug lost less blood and had a smaller decrease in haemoglobin concentration.
|
|
Credit: CHRIS SATTLBERGER/PANOS
|
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?